How AI Can Help Combat Antibiotic Resistance

Source:Indian Express
GS III: Science and Technology

Why in the News?

Researchers have reportedly used an artificial intelligence (AI) model called Omni to design bacteriophages to treat a patient suffering from a drug-resistant bacterial infection.

News in Brief

• Researchers used an AI model, Omnii-1, to design bacteriophages targeting a drug-resistant bacterial infection in a human patient.
• The AI-generated designs introduced genetic changes intended to improve the phages’ ability to recognise and infect the targeted bacteria.
• Laboratory tests showed that some engineered phages could infect and kill the resistant bacteria before the treatment was administered under regulatory authorisation.
• The approach could advance personalized treatment for antimicrobial resistance, but its clinical effectiveness, safety and wider applicability require further evaluation. The company’s report remains preliminary, and the patient’s treatment outcome has not been disclosed.

What are Bacteriophages?

• Bacteriophages, or phages, are viruses that infect specific bacteria and can destroy them.
• They are found naturally in the environment and are being studied as an alternative or complement to antibiotics.
• Unlike conventional antibiotics, which may affect a range of bacteria, many phages target particular bacterial strains.

How phage therapy works;

• The phage recognizes and attaches to a susceptible bacterium.
• It introduces its genetic material into the bacterial cell.
• The virus replicates inside the bacterium.
• In the case of a lytic phage, the bacterial cell breaks open, releasing new phages that can infect other susceptible bacteria.

How is AI used in Phage Therapy?

• The biotechnology start-up Radical Numerics developed an AI model called Omnii-1 to help design phages against antibiotic-resistant bacteria.
• The process involves;
  • Identifying the target: Researchers study the bacterial strain responsible for the patient’s infection.
  • AI-assisted design: The model analyses biological data and proposes genetic changes that could help a phage recognise the target bacteria.
  • Laboratory testing: Researchers synthesise the designed DNA and test whether viable phages can be produced and whether they can infect the targeted bacteria.
  • Clinical application: Following safety assessments and regulatory authorisation, the investigational phages were administered to a patient under a compassionate-use pathway.
• The researches reported that the engineered phages killed the patient’s resistant bacterial strain in laboratory tests.
• However, the patient’s clinical outcome has not been publicly established, and the findings have not yet been peer-reviewed.

Why is this development significant?

• Combating antimicrobial resistance (AMR)
  • Antimicrobial resistance occurs when microorganisms evolve mechanisms that make medicines less effective against them.
  • AI-assisted phage design could provide additional treatment options when conventional antibiotics fail.
• Personalized medicine
  • Phages could be designed to target the particular bacterial strain causing an individual’s infection, supporting more precise treatment.
• Faster therapeutic development
  • Finding a suitable phage through conventional methods can be time-consuming.
  • AI could help researchers identify promising candidates and reduce the time required to develop personalised treatments.
• Reducing dependence on conventional antibiotics
  • Phage therapy could complement existing antimicrobial treatments and potentially help reduce reliance on antibiotics in selected cases.
• Advancing biotechnology
  • The development demonstrates how AI can move beyond analyzing biological data to helping scientists design biological systems for potential medical applications.

Relevance to India

• India faces a significant public health challenge from antimicrobial resistance, making the development of new treatment strategies particularly relevant.
  • National Action Plan on Antimicrobial Resistance: AI-assisted phage therapy could complement broader efforts to improve antimicrobial stewardship, infection prevention and surveillance.
  • Biotechnology research: Indian research institutions can explore the application of AI in genomics, microbiology and therapeutic development.
  • Healthcare preparedness: Stronger diagnostic capabilities and laboratory infrastructure would help identify suitable patients and evaluate emerging therapies.
  • Biosecurity governance: India needs appropriate oversight of AI-enabled biological research to balance scientific innovation with public safety.
• Phage therapy should be viewed as a potential addition to India’s antimicrobial resistance response, not as an established replacement for antibiotics.

Challenges and Concerns

• Despite its potential, AI-assisted phage therapy faces several challenges.
• Phages are often specific to particular bacterial strains, limiting their effectiveness against other strains.
• Bacteria may also develop resistance to phages over time.
• Further, successful laboratory results do not guarantee the same outcomes in human patients, and possible immune reactions and unintended effects require careful assessment.
• Regulatory approval, specialised production and the high cost of developing personalised treatments may also limit wider use.
• In addition, AI systems capable of designing biological sequences raise biosecurity concerns if misused.

Way Forward and Conclusion

AI-assisted phage therapy requires further clinical trials to establish its safety and effectiveness. Strengthening rapid diagnostics, promoting collaboration among AI researchers and medical experts, and developing strategies to address bacterial resistance can improve its potential. At the same time, responsible AI governance, strong biosecurity safeguards and affordable access must remain priorities.

With scientific validation and appropriate regulation, AI-designed phages could become a valuable addition to the fight against antimicrobial resistance, complementing rather than conventional antibiotics.

Daily Current Affairs: Click Here

Rate this Article and Leave Feedback